SubTitle20-631-1_20-631-3. Collaborative Drug Therapy Management  


Sec. 20-631-1. Competency requirements
Latest version.

To qualify for participation in a collaborative drug therapy management agreement, a pharmacist shall be licensed in this state and shall meet at least one of the following qualifications:

(1) Bachelor of Science degree in pharmacy with 10 years of clinical experience, or a Pharm.D. degree;

(2) Certification by the Board of Pharmaceutical Specialties;

(3) Certification by the Commission for Certification in Geriatric Pharmacy;

(4) A credential in disease state management from the National Institute for Standards in Pharmacist Credentialing;

(5) Pharmacy residency accredited by the American Society of Health-System Pharmacists; or

(6) Completion of a disease state management certification program approved by the Accreditation Council for Pharmacy Education.

(Effective January 2, 2013)

Sec. 20-631-2. Content of a collaborative drug therapy management agreement
Latest version.

A collaborative drug therapy management agreement shall include:

(1) The types of prescriptive authority decisions the pharmacist may make (e.g., initiation, continuation or modification);

(2) Patients who are eligible for treatment;

(3) The types of diseases, drugs, or drug categories involved (there are no limitations on disease states or conditions);

(4) The procedures, decision criteria, plans, or guidelines the pharmacist is to follow when making therapeutic decisions, particularly when initiating or modifying drug therapy;

(5) Required training;

(6) A plan for periodic review, feedback and quality assurance; and

(7) Procedures for documenting prescribing decisions.

(Effective January 2, 2013)

Sec. 20-631-3. Content of patient protocol
Latest version.

A written protocol for a specific patient established pursuant to a collaborative drug therapy management agreement shall include, but need not be limited to, the following:

(1) The specific drug or drugs to be managed by the pharmacist;

(2) The terms and conditions under which drug therapy may be implemented, modified or discontinued;

(3) The conditions and events that the pharmacist is required to report to the physician;

(4) The laboratory tests that may be ordered by the pharmacist; and

(5) The drugs that may be administered by the pharmacist.

(Effective January 2, 2013)